Korean firms under spotlight for nasal spray protection against Covid-19

Yoo Joo-yeon and Minu Kim 2022. 8. 3. 14:15
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Several Korean companies are under the limelight with their exploration of simple nasal spray medicines to prevent respiratory viral infections, including coronavirus amid the resurgence of Covid-19 cases.

This new drug delivery technology is designed to remove viruses and germs while moistening the nasal mucosa.

According to industry sources on Tuesday, D.R.NANO, a startup founded by state-run Korea Institute of Science and Technology (KIST), successfully developed a nasal spray called ‘RHINOdeLIGHT’ to control viruses and bacteria that invade the nasal cavity. The company received medical device authorization of the device in April.

(From left) ‘RHINOdeLIGHT’ and "Coldmask. [Photo by each company]
The device has a virus-killing effect when the drug in the product is sprayed on the nasal mucosa and then exposed to an LED light source. The company applied for marketing approval of the nasal spray and its LED device as a bundled product with the Ministry of Food and Drug Safety.

Hanmi Pharmaceutical is planning to import a nasal spray made to prevent and treat Covid-19 infections from Austrian biotechnology firm Marinomed Biotech. The company aims to sell the device in the second half of this year upon regulatory approval. This product will be a follow-up to 'Coldmask', which Hanmi had sold until the first quarter of this year.

SK bioscience is another Korean company that is developing a Covid-19 preventive medicine in the form of a nasal spray. The product forms a protective layer on the inside of the nose to prevent the virus from penetrating the body. A small-scale protein layer disrupts the penetration of the virus, according to the company.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?